肥胖症的临床诊治策略和减重药物进展  

Clinical diagnosis and treatment strategies of obesity and the progress of weight reduction drugs

作　　者：童楚嫣 卜乐[1] 曲伸[1] Tong Chuyan;Bu Le;Qu Shen(Obesity Diagnosis and Treatment Center,Shanghai Tenth People′s Hospital,Shanghai 200072,China)

机构地区：[1]上海市第十人民医院肥胖症诊治中心,上海200072

出　　处：《中国药物与临床》2025年第6期347-352,共6页Chinese Remedies & Clinics

摘　　要：本文综述了肥胖症的临床诊治策略和减重药物的最新进展。肥胖是一种多因素引起的慢性病,其诊断标准主要依据体质量指数(BMI),但需结合其他指标进行综合评估。近年来,新型生物标志物和人工智能(AI)辅助分型为肥胖的诊断和治疗提供了新工具。在治疗方面,生活方式干预是基础,包括营养、运动和心理干预等。药物治疗方面,胰高血糖素样肽-1(GLP-1)受体激动剂等新型减重药物显示出显著效果。微创减重手术如内镜下袖状胃成形术等也取得了进展。AI技术在减重手术中的应用提高了手术的精准性和安全性。总之,肥胖的临床管理正迈向精准化与个体化,为患者提供了更多有效的治疗选择。This article reviews the latest advancements in the clinical diagnosis and treatment of obesity.Obesity is a chronic condition caused by multiple factors,and its diagnosis primarily relies on body mass index(BMI),but a comprehensive assessment requires the consideration of other indicators as well.In recent years,novel biomarkers and artificial intelligence(AI)-assisted diagnosis have provided new tools for the diagnosis and treatment of obesity.Treatment strategies typically begin with lifestyle interventions,which include nutrition,exercise,and psychological support.In terms of medication,new weight-loss drugs such as GLP-1 receptor agonists have shown promising results.Additionally,minimally invasive weight-loss surgeries,such as endoscopic sleeve gastro-plasty,have made significant progress.The application of AI technology in weight-loss surgery has improved the precision and safety of these procedures.In conclusion,the clinical management of obesity is shifting towards pre-cision and individualization,offering more effective treatment options for patients.

关 键 词：肥胖症 诊断标准 治疗策略 减重药物 AI辅助治疗 

分 类 号：R58[医药卫生—内分泌]